PMID- 36107291
OWN - NLM
STAT- MEDLINE
DCOM- 20230104
LR  - 20230111
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
VI  - 55
IP  - 1
DP  - 2023 Jan
TI  - Inhibitory effects of Hydrocotyle ramiflora on testosterone-induced benign 
      prostatic hyperplasia in rats.
PG  - 17-28
LID - 10.1007/s11255-022-03362-7 [doi]
AB  - PURPOSE: Benign prostatic hyperplasia (BPH) is a urogenital disorder that affects 
      approximately 85% of males who are over 50 years of age. Hydrocotyle ramiflora 
      (HR), belonging to Apiaceae family, is used to treat urinary system diseases such 
      as urine retention in traditional Chinese herbal medicine. In this study, we 
      evaluated the effects of HR in the BPH animal model. METHODS: We induced BPH in 
      rats via subcutaneous (sc) injections of testosterone propionate (TP, 3 mg/kg). 
      Rats were also administered HR (150 mg/kg), finasteride (10 mg/kg), or vehicle 
      via oral gavage. After induction, prostate glands were collected, weighed, and 
      processed for further analysis, including histopathological examination and 
      immunohistochemistry. In addition, the mRNA expression of inflammatory cytokines 
      in prostatic tissues was determined by quantitative real-time PCR (qRT-PCR). The 
      protein expression of pro-apoptotic markers was examined using western blotting. 
      RESULTS: HR treatment significantly reduced the prostate weight, epithelial 
      thickness, and proliferating cell nuclear antigen (PCNA) expression, with the 
      levels of cleaved caspase-3 and Bcl-2-associated X (Bax) protein considerably 
      increased compared to BPH group. HR also decreased inflammatory cell infiltration 
      and pro-inflammatory cytokine levels compared with BPH group. Furthermore, the 
      expression of phosphor-nuclear factor-kappaB (NF-kappaB), cyclooxygenase-2 (COX-2), and 
      inducible nitric oxide synthase (iNOS) were reduced by HR treatment. CONCLUSION: 
      These results indicate that HR suppresses the development of BPH associated with 
      anti-proliferative, pro-apoptotic, and anti-inflammatory effects, suggesting it 
      is a potential alternative therapeutic agent for BPH.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature B.V.
FAU - Park, Suyoung
AU  - Park S
AD  - Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam 
      National University, 99, Daehak-ro, Yuseong-gu, Daejeon, 34134, South Korea.
FAU - Hwang, Youn-Hwan
AU  - Hwang YH
AD  - Herbal Medicine Research Division, Korea Institute of Oriental Medicine, 1672, 
      Yuseong-daero, Yuseong-gu, Daejeon, 34054, South Korea.
FAU - Baek, Eun-Bok
AU  - Baek EB
AD  - Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam 
      National University, 99, Daehak-ro, Yuseong-gu, Daejeon, 34134, South Korea.
FAU - Hong, Eun-Ju
AU  - Hong EJ
AD  - Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam 
      National University, 99, Daehak-ro, Yuseong-gu, Daejeon, 34134, South Korea.
FAU - Won, Young-Suk
AU  - Won YS
AD  - Laboratory Animal Resource Center, Korea Research Institute of Bioscience and 
      Biotechnology, 30, Yeongudanji-ro, Cheongwon-gu, Cheongju, 28116, South Korea.
FAU - Kwun, Hyo-Jung
AU  - Kwun HJ
AD  - Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam 
      National University, 99, Daehak-ro, Yuseong-gu, Daejeon, 34134, South Korea. 
      hyojung@cnu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20220915
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - 3XMK78S47O (Testosterone)
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Male
MH  - Humans
MH  - Rats
MH  - Animals
MH  - *Prostatic Hyperplasia/chemically induced/drug therapy/metabolism
MH  - Testosterone/therapeutic use
MH  - *Centella
MH  - Rats, Sprague-Dawley
MH  - Plant Extracts/adverse effects
OTO - NOTNLM
OT  - Apoptosis
OT  - Benign prostatic hyperplasia
OT  - Hydrocotyle ramiflora
OT  - Inflammation
OT  - Proliferation
EDAT- 2022/09/16 06:00
MHDA- 2023/01/05 06:00
CRDT- 2022/09/15 11:20
PHST- 2022/07/25 00:00 [received]
PHST- 2022/09/05 00:00 [accepted]
PHST- 2022/09/16 06:00 [pubmed]
PHST- 2023/01/05 06:00 [medline]
PHST- 2022/09/15 11:20 [entrez]
AID - 10.1007/s11255-022-03362-7 [pii]
AID - 10.1007/s11255-022-03362-7 [doi]
PST - ppublish
SO  - Int Urol Nephrol. 2023 Jan;55(1):17-28. doi: 10.1007/s11255-022-03362-7. Epub 
      2022 Sep 15.